Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this clinical trial publication.

The researchers report here 13 additional patients with migraine who simultaneously used rimegepant and either erenumab, fremanezumab, or galcanezumab and assess the rate of on-treatment adverse events (AEs).

Who Took Part

The abstract describes 2 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

This was a substudy nested within a multicenter, open-label, long-term safety study in adults with 2-14 monthly migraine attacks of moderate to severe pain intensity.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

Being open-label, the CGRP (Calcitonin Gene-Related Peptide) study did not mask who received what.

Running at several centres spread the CGRP (Calcitonin Gene-Related Peptide) study over different clinics and patient groups.

What Was Measured

The researchers report here 13 additional patients with migraine who simultaneously used rimegepant and either erenumab, fremanezumab, or galcanezumab and assess the rate of on-treatment adverse events (AEs).

The subject headings attached to it are Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists, Drug-Related Side Effects and Adverse Reactions, Migraine Disorders and Piperidines.

The authors tagged it with the keywords prevention and rimegepant.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of CGRP (Calcitonin Gene-Related Peptide) in 2 patients in people with migraine.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Headache), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.